Patents by Inventor Stefan Laufer

Stefan Laufer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PROTEIN KINASE MKK4 INHIBITORS FOR PROMOTING LIVER REGENERATION OR REDUCING OR PREVENTING HEPATOCYTE DEATH
    Publication number: 20240116931
    Abstract: The invention relates to pyrazolo-pyridine compounds which inhibit mitogen-activated protein kinase kinase 4 (MKK4) and in particular, selectively inhibit MKK4 over protein kinases JNK1 and MKK7. The compounds are useful for promoting liver regeneration or reducing or preventing hepatocyte death. They are further useful for treating osteoarthritis or rheumatoid arthritis, or CNS-related diseases.
    Type: Application
    Filed: November 8, 2023
    Publication date: April 11, 2024
    Applicant: HEPAREGENIX GMBH
    Inventors: Brent PRAEFKE, Philip KLÖVEKORN, Roland SELIG, Wolfgang ALBRECHT, Stefan LAUFER
  • PROTEIN-PROTEIN INTERACTION MODULATORS OF AURORA KINASE A AND THEIR USE IN THE PREVENTION AND/OR TREATMENT OF CANCER
    Publication number: 20240101538
    Abstract: The present invention relates to compounds that modulate the conformation of Aurora Kinase A (AURKA). The compounds of the present invention are also modulators of the interactome of AURKA, and preferably alter the protein-protein interaction of AURKA with binding proteins, such as MYC and/or TPX2. The present invention also pertains to the use of such compounds in the prevention and/or treatment of proliferative diseases, such as cancer, and kits comprising the same.
    Type: Application
    Filed: November 5, 2021
    Publication date: March 28, 2024
    Inventors: Juliander J. REINER, Tatu PANTSAR, Dirk FLÖTGEN, Stefan LAUFER, Lars ZENDER, Melanie HENNING
  • Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
    Patent number: 11912701
    Abstract: The invention relates to compounds of formula (I) which are inhibitors of MKK4 (mitogen-activated protein kinase kinase 4) and their use in promoting liver regeneration or reducing or preventing hepatocyte death. The compounds selectively inhibit protein kinase MKK4 over protein kinases JNK and MKK7. (I), wherein Rx, Ry, Rz and Rzz are selected from: a) Rx and Ry are F and Rz and Rzz are H; b) Rx, Ry and Rzz are independently halogen and Rz is H; c) Rx Rz and Rzz are independently halogen and Ry is H; and d) Rx Ry and Rz are independently halogen and Rzz is H.
    Type: Grant
    Filed: July 16, 2019
    Date of Patent: February 27, 2024
    Assignee: HepaRegeniX GmbH
    Inventors: Wolfgang Albrecht, Stefan Laufer, Roland Selig, Phillip Klövekorn, Bent Präfke
  • Protein kinase MKK4 inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
    Patent number: 11858927
    Abstract: The invention relates to pyrazolo-pyridine compounds which inhibit mitogen-activated protein kinase kinase 4 (MKK4) and in particular, selectively inhibit MKK4 over protein kinases JNK1 and MKK7. The compounds are useful for promoting liver regeneration or reducing or preventing hepatocyte death. They are further useful for treating osteoarthritis or rheumatoid arthritis, or CNS-related diseases.
    Type: Grant
    Filed: January 30, 2019
    Date of Patent: January 2, 2024
    Assignee: HepaRegeniX GmbH
    Inventors: Bent Praefke, Philip Klövekorn, Roland Selig, Wolfgang Albrecht, Stefan Laufer
  • MUTANT SELECTIVE EGFR INHIBITORS AND METHODS OF USE THEREOF
    Publication number: 20230406838
    Abstract: The disclosure relates to compounds that act as inhibitors of epidermal growth factor receptor (EGFR); pharmaceutical compositions comprising the compounds; and methods of treating or preventing kinase-mediated disorders, including cancer and other proliferation diseases.
    Type: Application
    Filed: March 23, 2023
    Publication date: December 21, 2023
    Inventors: David Heppner, Michael Eck, Stefan Laufer, Florian Wittlinger, Marcel Guenther
  • IMIDAZO[4,5-C]QUINOLINE COMPOUNDS AND THEIR USE AS ATM KINASE INHIBITORS
    Publication number: 20230348462
    Abstract: The present invention relates to imidazo[4,5-c]quinoline compounds and to their use in the inhibition, regulation and/or modulation of signal transduction by ATM kinase and, in particular, for the treatment of ATM mediated diseases, especially cancer.
    Type: Application
    Filed: May 1, 2023
    Publication date: November 2, 2023
    Applicants: Deutsches Krebsforschungszentrum, Eberhard Karls Universitat, Universitatsklinikum Tubingen
    Inventors: Stefan Laufer, Michael Forster, Teodor Dimitrov, Lars Zender, Athina Moschopoulou
  • Tricyclic protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
    Patent number: 11731968
    Abstract: Tricyclic mitogen-activated protein kinases kinase 4 (MKK4) inhibitor compounds useful for promoting liver regeneration or reducing hepatocyte death by selectively inhibiting MKK4 over protein kinases JNK and MKK7.
    Type: Grant
    Filed: June 18, 2019
    Date of Patent: August 22, 2023
    Assignee: HepaRegeniX GmbH
    Inventors: Michael Juchum, Roland Selig, Stefan Laufer, Wolfgang Albrecht
  • 3-BENZOYL-1H-PYRROLO[2,3-B]PYRIDINE DERIVATIVES AS MKK4 INHIBITORS FOR TREATING LIVER DISEASES
    Publication number: 20230088395
    Abstract: The invention relates to compounds of formula (I) which are inhibitors of MKK4 (mitogen-activated protein kinase kinase 4) and their use in promoting liver regeneration or reducing or preventing hepatocyte death. The compounds selectively inhibit protein kinase MKK4 over protein kinases JNK1 and MKK7. In formula (I), especially, Rw is —NR10SO2R12; either a) Rx and Ry are F and Rz and Rzz are H; or b) Rx, Ry and Rzz are independently halogen and Rz is H; R5 is substituted phenyl or pyrimidinyl.
    Type: Application
    Filed: January 13, 2021
    Publication date: March 23, 2023
    Inventors: Roland SELIG, Stefan LAUFER, Wolfgang ALBRECHT
  • CENTRALLY ACTIVE P38ALPHA INHIBITING COMPOUNDS
    Publication number: 20230017312
    Abstract: Compounds that are inhibitors of p38alpha and centrally available are described.
    Type: Application
    Filed: August 26, 2020
    Publication date: January 19, 2023
    Applicant: Synovo GmbH
    Inventors: Stefan Laufer, Wolfgang Albrecht, Pierre Koch, Niklas Walter
  • HETEROARYL-SUBSTITUTED PYRAZOLO-PYRIDINE PROTEIN KINASE INHIBITORS FOR PROMOTING LIVER REGENERATION OR REDUCING OR PREVENTING HEPATOCYTE DEATH
    Publication number: 20220340561
    Abstract: The invention relates to pyrazolo-pyridine compounds which inhibit mitogen-activated protein kinase kinase 4 (MKK4) and in particular, selectively inhibit MKK4 over protein kinases JNK1 and MKK7. The compounds are useful for promoting liver regeneration or reducing or preventing hepatocyte death. They are further useful for treating osteoarthritis or rheumatoid arthritis, or CNS-related diseases.
    Type: Application
    Filed: July 27, 2020
    Publication date: October 27, 2022
    Inventors: Bent PFAFFENROT, Roland SELIG, Stefan LAUFER, Wolfgang ALBRECHT
  • PROTEIN KINASE INHIBITORS FOR PROMOTING LIVER REGENERATION OR REDUCING OR PREVENTING HEPATOCYTE DEATH
    Publication number: 20220281864
    Abstract: The invention relates to compounds of formula (I) which are inhibitors of MKK4 (mitogen-activated protein kinase kinase 4) and their use in promoting liver regeneration or reducing or preventing hepatocyte death. The compounds selectively inhibit protein kinase MKK4 over protein kinases JNK and MKK7.
    Type: Application
    Filed: July 16, 2019
    Publication date: September 8, 2022
    Inventors: Wolfgang ALBRECHT, Stefan LAUFER, Roland SELIG, Phillip KLÖVEKORN, Bent PRÄFKE
  • TRICYCLIC PROTEIN KINASE INHIBITORS FOR PROMOTING LIVER REGENERATION OR REDUCING OR PREVENTING HEPATOCYTE DEATH
    Publication number: 20210261545
    Abstract: The invention relates to tricyclic compounds which are MKK4 (mitogen-activated protein kinase kinase 4) inhibitors which selectively inhibit protein kinase kinase MKK4 over protein kinases JNK and MKK7. They are useful for promoting liver regeneration or reducing or preventing hepatocyte death.
    Type: Application
    Filed: June 18, 2019
    Publication date: August 26, 2021
    Inventors: Michael JUCHUM, Roland SELIG, Stefan LAUFER, Wolfgang ALBRECHT
  • Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
    Patent number: 11040027
    Abstract: The invention relates to MKK4 (mitogen-activated protein kinase 4) and their use in promoting liver regeneration or reducing or preventing hepatocyte death. The MKK4 inhibitors selectively inhibit protein kinase MKK4 over protein kinases JNK and MKK7.
    Type: Grant
    Filed: January 17, 2018
    Date of Patent: June 22, 2021
    Assignee: Heparegenix GMBH
    Inventors: Wolfgang Albrecht, Stefan Laufer, Roland Selig, Phillip Klövekorn, Bent Präfke
  • PROTEIN KINASE MKK4 INHIBITORS FOR PROMOTING LIVER REGENERATION OR REDUCING OR PREVENTING HEPATOCYTE DEATH
    Publication number: 20210078995
    Abstract: The invention relates to pyrazolo-pyridine compounds which inhibit mitogen-activated protein kinase kinase 4 (MKK4) and in particular, selectively inhibit MKK4 over protein kinases JNK1 and MKK7. The compounds are useful for promoting liver regeneration or reducing or preventing hepatocyte death. They are further useful for treating osteoarthritis or rheumatoid arthritis, or CNS-related diseases.
    Type: Application
    Filed: January 30, 2019
    Publication date: March 18, 2021
    Inventors: Bent PRAEFKE, Philip KLÖVEKORN, Roland SELIG, Wolfgang ALBRECHT, Stefan LAUFER
  • PROTEIN KINASE INHIBITORS FOR PROMOTING LIVER REGENERATION OR REDUCING OR PREVENTING HEPATOCYTE DEATH
    Publication number: 20190365723
    Abstract: The invention relates to MKK4 (mitogen-activated protein kinase 4) and their use in promoting liver regeneration or reducing or preventing hepatocyte death. The MKK4 inhibitors selectively inhibit protein kinase MKK4 over protein kinases JNK and MKK7.
    Type: Application
    Filed: January 17, 2018
    Publication date: December 5, 2019
    Inventors: Wolfgang Albrecht, Stefan Laufer, Roland Selig, Phillip Klövekorn, Bent Präfke
  • Dibenzocycloheptatone derivatives and pharmaceutical agents containing said compounds
    Patent number: 8633312
    Abstract: The present invention relates to compounds of the formula I wherein R1, R2, R3, R4, X and Y have the meanings given in the description. The compounds have an action which is immunomodulating and inhibits or regulates the release of IL-1? and/or TNF-?. They can therefore be used for treatment of diseases connected with a disturbance in the immune system.
    Type: Grant
    Filed: October 9, 2009
    Date of Patent: January 21, 2014
    Assignee: c-a-i-r biosciences GmbH
    Inventors: Stefan Laufer, Wolfgang Albrecht
  • Choline and tromethamine salt of licofelone
    Patent number: 8519155
    Abstract: The present invention relates to the choline and tromethamine salt of Licofelone.
    Type: Grant
    Filed: October 30, 2009
    Date of Patent: August 27, 2013
    Assignee: c-a-i-r biosciences GmbH
    Inventors: Wolfgang Albrecht, Hans-Günter Striegel, Stefan Laufer
  • DIBENZOCYCLOHEPTATONE DERIVATIVES AND PHARMACEUTICAL AGENTS CONTAINING SAID COMPOUNDS
    Publication number: 20120115862
    Abstract: The present invention relates to compounds of the formula I wherein R1, R2, R3, R4, X and Y have the meanings given in the description. The compounds have an action which is immunomodulating and inhibits or regulates the release of IL-1? and/or TNF-?. They can therefore be used for treatment of diseases connected with a disturbance in the immune system.
    Type: Application
    Filed: October 9, 2009
    Publication date: May 10, 2012
    Inventors: Stefan Laufer, Wolfgang Albrecht
  • 2-sulfanyl-substituted imidazole derivatives and their use as cytokine inhibitors
    Patent number: 8143294
    Abstract: The invention relates to 2-thio-substituted imidazole derivatives of the Formula I, and to methods of use thereof.
    Type: Grant
    Filed: December 31, 2008
    Date of Patent: March 27, 2012
    Inventors: Michael Burnet, Stefan Laufer, Pierre Koch
  • CHOLINE AND TROMETHAMINE SALT OF LICOFELONE
    Publication number: 20120010261
    Abstract: The present invention relates to the choline and tromethamine salt of Licofelone.
    Type: Application
    Filed: October 30, 2009
    Publication date: January 12, 2012
    Applicant: c-a-i-r biosciences GmbH
    Inventors: Wolfgang Albrecht, Hans-Günter Striegel, Stefan Laufer